A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 2, 2007, Pages 445-452

  Anné, Pramila Rani ^a   Machtay, Mitchell ^b   Rosenthal, David I ^c   Brizel, David M ^d   Morrison, William H ^c   Irwin, David H ^e   Chougule, Prakash B ^f   Estopinal, Noel C ^g   Berson, Anthony ^h   Curran Jr , Walter J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Alta Bates Comprehensive Cancer Center   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

^g Comprehensive Cancer Institute ^*  (United States)

^h ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

head and neck cancer; Radioprotection; Subcutaneous amifostine; Xerostomia

Indexed keywords

BIOMEDICAL ENGINEERING; DEHYDRATION; RADIOTHERAPY; TUMORS;

HEAD AND NECK CANCER; RADIOPROTECTION; SUBCUTANEOUS AMIFOSTINE; XEROSTOMIA;

PATIENT TREATMENT;

AMIFOSTINE; DICLOXACILLIN; PILOCARPINE; PSEUDOMONIC ACID; STEROID;

ADULT; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; BRONCHITIS; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA MULTIFORME; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; INCIDENCE; INJECTION SITE REACTION; MALE; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHOTODERMATOSIS; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; RIGOR; SIDE EFFECT; TRACHEITIS; VOMITING; WEIGHT; XEROSTOMIA;

ADULT; AGED; AMIFOSTINE; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NAUSEA; PATIENT COMPLIANCE; RADIATION-PROTECTIVE AGENTS; VOMITING; XEROSTOMIA;

EID: 33846233367     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.08.044     Document Type: Article

References (24)

1. Yuhas J.M., and Storer J.B. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 42 (1969) 331-335
2. Andreassen C.N., Grau C., and Lindegaard J.C. Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 13 (2003) 62-72
3. Yuhas J.M. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 63 (1979) 971-976
4. Yuhas J.M., and Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 64 (1980) 57-64
5. Yuhas J.M., Spellman J.M., and Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3 (1980) 211-216
6. Yuhas J.M., Spellman J.M., Jordan S.W., et al. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 42 (1980) 574-585
7. Yuhas J.M. A more general role for WR-2721 in cancer therapy. Br J Cancer 41 (1980) 832-834
8. Green D., Bensely D., and Schein P. Preclinical evaluation of WR-151327: an orally active chemotherapy protector. Cancer Res 54 (1994) 738-741
9. Dorr R.T., Lagel K., and McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Eur J Cancer 32A Suppl. 4 (1996) S21-S25
10. List A.F., Heaton R., Glinsmann-Gibson B., et al. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23 (1996) 58-63
11. Taylor C.W., Wang L.M., List A.F., et al. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 33 (1997) 1693-1698
12. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
13. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 18 (2000) 2226-2233
14. Wasserman T., Mackowiak J.I., Brizel D.M., et al. Effect of amifostine on patient assessed clinical benefit in irradiated head-and-neck cancer. Int J Radiat Oncol Biol Phys 48 (2000) 1035-1039
15. Wasserman T.H., Brizel D.M., Henke M., et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, Phase III trial. Int J Radiat Oncol Biol Phys 63 (2005) 985-990
16. Shaw L.M., Bonner H.S., Schuchter L., et al. Pharmacokinetics of amifostine: effects of dose and method of administration. Semin Oncol 26 (1999) 34-36
17. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
18. Arbuck SG, Ivy SP, Setser A. et al. The Revised Common Toxicity Criteria: Version 2.0. Availablr at: http://ctep.info.nih.gov.
19. Boccia R., Anné P.R., Bourhis J., et al. Assessment and management of cutaneous reactions with amifostine administration: Findings of the Ethyol (amifostine) Cutaneous Treatment Advisory Panel (ECTAP). Int J Radiat Oncol Biol Phys 60 (2004) 302-309
20. Koukourakis M.I., Romanidis K., Froudarakis M., et al. Concurrent administration of docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 87 (2002) 385-392
21. Capizzi R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26 (1999) 3-21
22. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17 (1999) 3333-3355
23. Schuchter L.M., Hensley M.L., Meropol N.J., et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20 (2002) 2895-2903
24. Bardet E., Martin L., Calais G., et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 29 (2002) 57-60